DexCom Total Revenue decreased by 5.4% to $1.19B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.0%, from $1.04B to $1.19B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 17.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $595.10M | $650.20M | $698.20M | $628.80M | $696.20M | $769.60M | $815.20M | $741.50M | $871.30M | $975.00M | $1.03B | $921.00M | $1.00B | $994.20M | $1.11B | $1.04B | $1.16B | $1.21B | $1.26B | $1.19B |
| QoQ Change | — | +9.3% | +7.4% | -9.9% | +10.7% | +10.5% | +5.9% | -9.0% | +17.5% | +11.9% | +6.1% | -11.0% | +9.0% | -1.0% | +12.0% | -7.0% | +11.7% | +4.5% | +4.2% | -5.4% |
| YoY Change | — | — | — | — | +17.0% | +18.4% | +16.8% | +17.9% | +25.2% | +26.7% | +26.9% | +24.2% | +15.3% | +2.0% | +7.6% | +12.5% | +15.2% | +21.6% | +13.1% | +15.0% |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| International | $267.80M | $272.40M | $292.30M | $310.70M | $285.50M | $316.10M | $357.40M | $359.60M |
| Total | $921.00M | $1.00B | $994.20M | $1.11B | $1.04B | $1.16B | $1.21B | $1.19B |